Ligand Pharmaceuticals Incorporated Stock News

Ligand (LGND) delivered earnings and revenue surprises of 45.90% and 27.30%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three months ended March 31, 2020 and provided an operating forecast and program updates. Ligand management

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech Stocks Hitting 52-week Highs May 5) • Adverum Biotechnologies...

These 3 stocks appear to trade at bargain prices based on 2 key valuation ratios Continue reading...

Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck...

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Vertex Pharmaceuticals (VRTX) and ANI Pharmaceuticals

Ligand (LGND) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ligand (LGND) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ligand has 'significant upside' if remdesivir is approved, says Craig-Hallum Craig-Hallum LGND GILD

Fevertree Drinks price target lowered to 2,250 GBp from 2,900 GBp at Berenberg Berenberg FQVTF

The Fly is a leading digital publisher of real-time financial news. The Fly team scours all sources of company news and delivers short-form stories consisting of only market moving content.